EDucation and eXercise for gluteal tendinopathy in an Irish context (EDX-Ireland): findings from the LEAP-Ireland feasibility randomised controlled trial.

Musculoskelet Sci PractJun 26, 2026 (epub)

H P French, S Almousa, R Mellor et al.

✦ AI-curated · Sources linked

In 30 seconds

The LEAP-Ireland feasibility randomized controlled trial assessed the effectiveness of a 6-session EDucation and eXercise intervention for gluteal tendinopathy compared to usual care. Conducted with 65 participants (89% women, mean age 53.1 years), the study demonstrated a recruitment rate of 55% and a retention rate of 92% at 8 weeks, indicating feasibility for a larger trial.

Key findings

  • Recruitment rate was 55%, with 65 participants consenting to the study.
  • Retention rate was 92% at 8 weeks and 89% at 3 months.
  • 83% of participants were recruited via social media/community channels.
  • An estimated 134 participants would be needed for a future RCT.

Why it matters

Understanding the feasibility of interventions like EDX-Ireland is crucial for developing effective treatment strategies for gluteal tendinopathy, which can significantly impact patients' quality of life.

Source

Published in Musculoskelet Sci Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.